Details for Patent: 12,636,289
Which drugs does patent 12,636,289 protect, and when does it expire?
Patent 12,636,289 protects SUBVENITE and is included in one NDA.
Summary for Patent: 12,636,289
| Title: | Lamotrigine oral liquid suspension and use thereof |
| Abstract: | The present invention relates to an oral liquid suspension that includes lamotrigine and methods of medical treatment that include administering the oral liquid suspension. The oral liquid suspension has desirable physicochemical properties and technical attributes. The oral liquid suspension is useful in patients having difficulties in swallowing tablets and provide medical practitioners with additional options for dose titration. |
| Inventor(s): | Paul Sudhakar, Scott Boyer |
| Assignee: | Rowp Ip Holding Ii LLC |
| Application Number: | US18/170,185 |
|
Patent Claim Types: see list of patent claims | Formulation; Compound; Device; Dosage form; |
Drugs Protected by US Patent 12,636,289
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Owp Pharms | SUBVENITE | lamotrigine | SUSPENSION;ORAL | 218879-001 | Sep 16, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
